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Abstract
B-type natriuretic peptide (BNP) is often used as a complementary finding in the diagnostic
work-up of patients with aortic stenosis (AS). Whether soluble ST2, a new biomarker of car-
diac stretch, is associated with symptomatic status and outcome in asymptomatic AS is
unknown. sST2 and BNP levels were measured in 86 patients (74±13 years; 59 asymptom-
atic, 69%) with AS (<1.5 cm2) and preserved left ventricular ejection fraction who were fol-
lowed-up for 26±16 months. Both BNP and sST2 were associated with NYHA class but
sST2 (>23 ng/mL, AUC = 0.68, p<0.01) was more accurate to identify asymptomatic
patients or those who developed symptoms during follow-up. sST2 was independently
related to left atrial index (p<0.0001) and aortic valve area (p = 0.004; model R2 = 0.32). A
modest correlation was found with BNP (r = 0.4, p<0.01). During follow-up, 29 asymptom-
atic patients (34%) developed heart failure symptoms. With multivariable analysis, peak
aortic jet velocity (HR = 2.7, p = 0.007) and sST2 level (HR = 1.04, p = 0.03) were indepen-
dent predictors of cardiovascular events. In AS, sST2 levels could provide complementary
information regarding symptomatic status, new onset heart failure symptoms and outcome.
It might become a promising biomarker in these patients.
Introduction
Aortic stenosis (AS) is the most common valvular heart disease in western countries. Risk strat-
ification in asymptomatic patients and identifying characteristics of poor prognosis in symp-
tomatic subjects have become key elements in the evaluation of AS [1–3]. Aortic valve
replacement (AVR) is indicated in patients with severe AS when symptoms and/or left ventric-
ular (LV) systolic dysfunction (LV ejection fraction< 50%) develop [4–5]. However, LV ejec-
tion fraction often remains normal for long despite latent and potentially irreversible
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alterations in LV myocardial structure and function. Such LV remodelling process is already
observed in patients with moderate AS, precedes symptoms development and can trigger bio-
markers release (i.e. B-type natriuretic peptide (BNP)) [6]. In AS, the BNP level correlates with
valve area, diastolic function, functional status and symptomatic deterioration and may
improve risk stratification [7–9]. ST2, a member of the interleukin-1 receptor family, is a novel
biomarker of mechanical stress. ST2 is expressed both in a soluble isoform (measured in
serum) and in a transmembrane receptor isoform for which IL-33 serves as a ligand [10]. ST2
expression is upregulated in isolated cardiomyocytes exposed to mechanical strain and in
explanted aortic valve of patients with non-rheumatic AS [11–12]. Serum soluble ST2 (sST2)
levels are elevated and associated with outcomes in patients with acute myocardial infarction
and heart failure, independently of BNP [13–19]. Whether sST2 is increased in relation to the
symptomatic status and represents an independent marker of poor prognosis in AS is
unknown. In the present study, we evaluated sST2 in patients with AS as a potential marker of
disease severity, new onset heart failure symptoms and outcome.
Materials and Methods
The present study consisted of patients with moderate to severe AS (aortic valve area<1.5
cm2) and preserved left ventricular (LV) ejection fraction (>50%) examined at our Heart
Valve Clinic, CHU of Liège. All enrolled patients agreed to participate in our blood sample col-
lection (Biobank) for valvular heart disease. The institutional review board (« Comité d'Ethique
Hospitalo-Facultaire Universitaire de Liège ») approved the protocol and all patients gave writ-
ten informed consent. Demographics and clinical data were recorded in our Institutional elec-
tronic medical record at the time of initial visit in the echo lab. Use of cardiac medications,
laboratory results, and symptomatic status at the time of the initial echocardiogram were
recorded. Absence of symptoms was confirmed by a normal exercise testing. None of the
patients had concomitant moderate or severe valvular conditions other than AS, previous valve
surgery, complex congenital heart disease, supravalvular or subvalvular aortic stenosis, hyper-
trophic cardiomyopathy, plasma creatinine level>13 mg/dL, significant arrhythmia, acute and
chronic inflammatory disease.
A comprehensive transthoracic echocardiography was performed using VIVID 7 ultra-
sound system (General Electric Healthcare, Little Chalfont, UK) in all patients. All Doppler-
echocardiographic recordings were stored in digital format on a dedicated workstation for off-
line subsequent analysis. All echocardiographic measurements were performed as previously
described by our group. Of note, LV stroke volume was calculated using both the Doppler (LV
outflow tract area x LV outflow tract velocity—time integral measured by pulsed-wave Dopp-
ler) and the volumetric (bi-apical Simpson’s method) methods. Moreover, multiple transducer
positions were used to record peak aortic jet velocities. The highest transaortic velocity was
used for tracing of the time-velocity integral and to calculate pressure gradients. For each mea-
surement, at least two cardiac cycles were averaged. The peak E-wave of the mitral inflow was
measured using pulsed-wave Doppler. Tissue Doppler imaging with pulsed-wave Doppler at
the level of septal and lateral mitral annulus was used to measure e’ velocities. The average of
septal and lateral mitral annulus e’ peak velocity was used to calculate the E/e’ ratio.
Venous blood samples for BNP and sST2 measurements were drawn before echocardiogra-
phy, after 10 minutes of supine rest. Chilled ethylenediaminetetraacetic acid tubes were centri-
fuged immediately at 1000 x g (4°C) for 15 minutes. Separated plasma samples were processed
for BNP measurements by immunoassay (Biosite, Beckman Coulter, San Diego, California).
The inter- and intra-assay variation was 5% and 4%, respectively. The assay detection limit was
1 pg/ml. A predictive risk score, including BNP, gender and aortic valve peak velocity, was
sST2 in Aortic Stenosis
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calculated for each patient according to the recent work of Monin et al [9]. The ratio between
measured serum BNP level and maximal normal BNP level for age and sex (BNP ratio) was
also calculated for each patient [20,21]. Soluble ST2 was measured by a sandwich double
monoclonal antibody ELISA method (Quantikine1 ELISA, R&D Systems, Minneapolis, MN)
according to manufacturer’s instructions. The inter- and intra-assay variation was 6% and 5%,
respectively.
Follow-up information was obtained from interviews with the patients, their relatives or
their physicians every six to twelve months, according to current guidelines [4,5]. The begin-
ning of follow-up was considered the date of the initial echocardiogram at our institution and
the end points were the occurrence of new onset heart failure symptoms related events (death,
dyspnea, acute pulmonary edema) in the asymptomatic patients.
Data are given as mean values ± standard deviation (SD); categorical variables are described
as number and percentages. Differences between groups were analyzed for statistical signifi-
cance with the 1-way analysis of variance (ANOVA), χ2 test, or Fisher exact test as appropriate.
Correlations between echocardiographic data and biomarkers were assessed with linear regres-
sions. Independent predictors of biomarker levels were obtained with the use of stepwise multi-
ple linear regressions. Stepwise logistic regression analysis was used to determine the
predictors of symptomatic status. Probabilities of end point-free survival were obtained by
Kaplan-Meier estimates for the 2 groups and then compared by a 2-sided log-rank test. Cox
proportional-hazards models were used both in individual and multivariable analyses to iden-
tify the independent predictors of the occurrence of end-points. Variables with a univariable
value of p<0.10 were incorporated into the multivariable models. The selection of variables
included in the multivariate model was performed with a special care. To avoid colinearity
among a subset of several variables measuring the same phenomenon (e.g., aortic valve area,
peak aortic pressure gradient, mean aortic pressure gradient), we entered in the multivariate
models the variable that had the strongest association with event on univariable analysis. Val-
ues of p<0.05 were considered significant. Receiver-operator characteristic (ROC) curve analy-
sis was performed to determine the cut-off values that best distinguished the issue (e.g.,
symptoms, death or combined events) (AUC: Area under the curve). All statistical analyses
were performed with STATISTICA version 10 (StatSoft Inc, Tulsa, Okla).
Results
Of the 86 enrolled patients, 27 (31%) were classified as symptomatic at baseline (i.e. inclusion
visit) (Fig 1). Patients were followed-up for 26±16 months. During this period, a total of 8 (9%)
patients died from cardiovascular death. Of the 27 symptomatic patients, 12 had surgical aortic
valve replacement (4 with revascularization), 13 underwent a transcatheter aortic valve implan-
tation with a CoreValve bioprosthesis (high-surgical risk), and 2 refused any intervention. Six
of them died during follow-up and 2 were hospitalized for worsening symptoms (1 in acute
atrial fibrillation). Of the 59 asymptomatic patients, 25 patients developed heart failure symp-
toms (dyspnea in 23, dyspnea and angina in 3), 2 were hospitalized for acute pulmonary
edema, 20 underwent aortic valve replacement combined with coronary artery by-pass grafting
in 4, and 2 died (1 from refractory heart failure and 1 with heart failure symptoms treated med-
ically because of prohibitive high surgical risk). Hence, a total of 29 patients developed new
onset heart failure symptoms.
Compared with the 59 (69%) asymptomatic patients, symptomatic patients at study entry
did not differ in gender and presence of risk factors but were older (p = 0.03), had higher aortic
pressure gradients (p<0.001), smaller aortic valve area (p<0.001) and higher BNP (p<0.001)
and sST2 levels (p = 0.006) (Table 1). BNP and sST2 levels were not statistically different
sST2 in Aortic Stenosis
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according to gender. BNP was well correlated with age (r = 0.34, p<0.001), which was also true
for sST2 though at a lower extent (r = 0.26, p = 0.02). Both biomarkers increased with the
symptomatic status (BNP: 100±122 vs. 270±322 pg/mL; sST2: 21±8 vs. 27±11 ng/mL; p<0.001
for all) and the NYHA class (BNP: NYHA class I 100±122, class II 141±125, class III-IV 358
±256 pg/mL; sST2: NYHA class I 18±4, class II 20±8, class III-IV 33±9 ng/mL; p<0.001 for
class I/II vs. III-IV) (Fig 2). Risk score and BNP ratio were also higher in symptomatic patients
(p<0.05). In multivariable logistic regression analysis, after adjustment for age, severity of AS,
BNP, left atrial size, E/e’, and LV mass, independent determinants of symptoms were sST2
(odds-ratio [OR] = 1.1, 95% confidence interval [CI] = 1.0–1.3; p = 0.037) and mitral E/e’
(OR = 1.35, CI = 1.02–1.8; p = 0.025). Similar results were obtained when BNP ratio was used
instead of age and BNP (sST2: OR 1.07, CI = 1.008–1.15; p = 0.028; E/e’: OR 1.22, CI = 1.07–
1.40; p = 0.0036). Using ROC curve analysis, the best cut-off value to identify symptomatic
patients was 23 ng/mL for sST2 (AUC = 0.68, sensitivity = 60%, specificity = 74%, p<0.01).
In the overall population, plasma levels of BNP and sST2 were correlated with the severity
of AS, the degree of LV hypertrophy, the diastolic burden (left atrial area, E/e’) and with the LV
ejection fraction (Table 2). sST2 levels were also modestly correlated with BNP levels (r = 0.4,
p<0.01) (Fig 3). With multiple linear regression analysis, left atrial index (p<0.0001) and aor-
tic valve area (p = 0.004; model R2 = 0.32) were correlated with sST2 levels. Left atrial index
(p = 0.025) and E/e’ (p = 0.03; model R2 = 0.29) were determinants of BNP. In asymptomatic
patients, mean aortic pressure gradient and E/e’ were correlated with BNP, whereas aortic
valve area, LV mass, and left atrial size were correlated with sST2. E/e’ (p<0.001; model R2 =
Fig 1. Study population and follow-up.
doi:10.1371/journal.pone.0138940.g001
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0.47) was the only independent determinant of BNP. Aortic valve area (p = 0.006) and LV
mass (p = 0.004) were independent determinants of sST2 (model R2 = 0.27).
In the group of asymptomatic patients, those who experienced events (29 patients) during
follow-up tended to be older (p = 0.086), had more severe AS (higher aortic peak jet velocity
(p<0.001), smaller aortic valve area (p = 0.001)), larger left atrium (p = 0.011), higher BNP
(p = 0.013) and sST2 (p = 0.001) levels (Table 3). For the other clinical and echocardiographic
parameters, no significant correlation with the outcome was found (p> 0.1 for all). In the mul-
tivariable analysis, peak aortic jet velocity (HR = 2.7, p = 0.007) and sST2 level (HR = 1.04,
p = 0.03) were predictive of the outcome. When BNP ratio was used in the multivariable
model, peak aortic jet velocity (HR = 2.8, p = 0.007) and sST2 (HR = 1.04; p = 0.043) remained
predictive of the outcome. Using the previously identified cut-off (23 ng/mL) in the multivari-
able model, yielded to similar results where only peak aortic jet velocity (HR = 2.9, CI = 1.47–
5.7, p = 0.002) and sST2> 23 ng/mL (HR = 2.42, CI = 1.07–5.44, p = 0.033) remained indepen-
dent predictors. When the sST2 tertiles were used in the univariable models, significant differ-
ences were obtained between T1 and T3 (p = 0.026) but not between T1 and T2 (p = 0.17) or
T2 and T3 (p = 0.09) in terms of outcome.
Table 1. Demographic, Clinical and Echocardiographic characteristics according to the symptomatic status at study entry and follow-up.
Variables Asymptomatic all along,
(n = 30, 35%)
Symptomatic at follow-up,
(n = 29, 34%)
Symptomatic at study entry,




Age—years 70±16 72±13 82±6 <0.01
Male gender—no (%) 22 (73) 18 (62) 16 (59) 0.49
Hypertension—no (%) 19 (63) 20 (67) 20 (74) 0.68
Diabetes mellitus—no (%) 4 (13) 6 (21) 8 (30) 0.32
Hypercholesterolemia—no (%) 16 (53) 16 (55) 10 (37) 0.33
Current smoking—no (%) 7 (23) 9 (31) 13 (48) 0.14
Aortic Stenosis Severity
Aortic valve area—cm2 1.03±0.2 0.90±0.22 0.73±0.19 <0.01
Peak aortic velocity—m/sec 3.7±0.6 3.9±0.6 4.3±0.6 <0.01
Mean pressure gradient—mm Hg 33±11 42±15 47±15 <0.01
LV function
Indexed LV end-diastolic volume
—ml/m2
52±18 53±20 55±27 0.97
Indexed LV end-systolic volume—
ml/m2
21±8 20±8 20±6 0.96
LV ejection fraction—% 65±7 67±5 63±6.5 0.23
LV mass—g/m2 80±20 94±22 112±29 <0.01
Mitral E/e’ 11±5 12±5 17±6 <0.01
Left atrial area index 9.1±3 11±3 14±5 <0.01
Biomarkers
BNP (pg/mL) 76±74 126±154 270±322 <0.01
BNP ratio 0.97±1.05 1.7±3.3 2.9±3.7 0.04
Risk score 10±1.6 11.5±1.6 12.6±1.7 <0.01
sST2 (ng/mL) 17±4.4 24±10 27±11 <0.01
Values are means ± SD. LV denotes left ventricular.
doi:10.1371/journal.pone.0138940.t001
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Discussion
The main findings of this study are: (1) sST2 appears to be a new promising biomarker to sepa-
rate symptomatic from asymptomatic patients with AS, (2) sST2 is related to AS severity and
the extent of diastolic burden as assessed by the left atrial area, (3) high sST2 levels are likely
associated with outcomes in asymptomatic AS.
In the present study, there was a good association between the symptomatic status and
plasma levels of sST2. Interestingly, sST2 levels gradually increased with the NYHA class.
Fig 2. Plasma levels of sST2 at study entry in association with NYHA class.
doi:10.1371/journal.pone.0138940.g002
Table 2. Echocardiographic correlates of biomarkers.
Entire population Asymptomatic patients Symptomatic patients
Variables Log BNP Log sST2 Log BNP Log sST2 Log BNP Log sST2
r p r p r p r p r p r p
Aortic Stenosis Severity
Aortic valve area 0.36 <0.01 0.33 <0.01 0.23 0.07 0.29 0.029 0.26 0.022 0.21 0.048
Peak aortic velocity 0.27 0.01 0.21 0.06 0.24 0.06 0.28 0.039 0.14 0.28 0.15 0.23
Mean pressure gradient 0.28 0.008 0.28 0.11 0.32 0.012 0.37 0.006 0.11 0.49 0.08 0.59
LV function
LV end-diastolic volume 0.22 0.16 0.08 0.64 0.23 0.17 0.06 0.72 0.17 0.38 0.22 0.09
LV end-systolic volume 0.19 0.25 0.06 0.71 0.19 0.25 0.014 0.93 0.21 0.10 0.19 0.11
LV ejection fraction 0.30 0.01 0.28 0.034 0.14 0.33 0.03 0.83 0.53 0.038 0.52 0.02
LV mass 0.29 0.016 0.43 <0.01 0.04 0.76 0.37 0.01 0.21 0.34 0.27 0.06
Mitral E/e’ 0.45 <0.01 0.26 0.036 0.66 <0.001 0.22 0.13 0.14 0.51 0.11 0.59
Left atrial area index 0.49 <0.01 0.49 <0.01 0.24 0.086 0.37 0.008 0.44 0.035 0.41 0.03
LV denotes left ventricular.
doi:10.1371/journal.pone.0138940.t002
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Conversely, although BNP was univariately associated with the NYHA class and correlated
modestly with sST2 levels, it did not emerge as an independent determinant of the symptom-
atic status. Although adjusted for age and sex, BNP ratio [20, 21] did not improve the predic-
tive accuracy of BNP. sST2 could thus be considered as an accurate discriminator between
early symptoms of heart failure and normal effort tolerance. Similarly, both BNP (BNP ratio)
and sST2 levels univariately predicted the onset of symptoms during follow-up in asymptom-
atic patients with AS. However, in the multivariable Cox regression analysis, only sST2 pre-
dicted symptomatic deterioration over time. Our data extended those described in patients
with heart failure in whom sST2 concentrations correlated with clinical indices of severity,
such as NYHA functional class [14–16]. BNP is known to be produced by the myocardium in
response to pressure overload whereas sST2 protein is released under chronic inflammatory
Fig 3. Correlation between sST2 and BNP levels.
doi:10.1371/journal.pone.0138940.g003
Table 3. Univariable data included in the multivariable outcomemodels in asymptomatic patients.
Variables Onset of Heart failure symptoms
HR (95 percent CI) P
Age 1.03 (0.90–1.06) 0.086
Aortic valve area . . . . . .*
Peak aortic velocity 2.8 (1.6–5.07) <0.001
Left atrial area index 1.19 (1.04–1.38) 0.011
BNP 2.5 (1.21–5.23) 0.013
sST2 1.05 (1.02–1.09) 0.001
HR denotes Hazard-Ratio, CI denotes conﬁdence interval, LV left ventricular.
*The ellipsis means that the aortic valve area, though signiﬁcant in our univariable analysis (p = 0.001),
was not included in the multivariable model because it was less predictive than peak aortic velocity for
heart failure symptoms (p<0.001).
doi:10.1371/journal.pone.0138940.t003
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conditions and in response to cardiac mechanical stress [10–12]. sST2 acts as a “decoy recep-
tor” for IL-33, negatively regulating IL-33 signalling at membrane bound ST2. IL-33 bound to
sST2 is removed from the biologically active pool and can no longer serve its functions. IL-33
exerts antihypertrophic effects in cultured cardiomyocytes that are antagonized by administra-
tion of sST2, and reduces myocardial fibrosis and cardiomyocyte hypertrophy in response to
pressure overload in mice [11]. In patients with pressure overload (AS) hypertrophy, diastolic
load is the predominant hemodynamic factor that contributes to ST2 production [22]. Main
sources of circulating sST2 include the endothelial cells and cardiomyocytes [23]. Moreover,
inflammatory conditions of AS may enhance the capacity of these cells to secrete sST2 [24]. In
our study, sST2 related to indexes of diastolic burden (left atrial size, E/e’), LV hypertrophy,
severity of AS and LV systolic function (ejection fraction); factors that are the hallmark of a
more advanced disease process. Similar findings were observed in patients with myocardial
infarction, acute dyspnea or heart failure [14–16, 25]. Interestingly, it was recently shown that
ST2 expression levels were markedly up-regulated in non-rheumatic AS compared with aortic
regurgitant valves, suggesting that IL-33/ST2 pathway may be involved in the pathophysiology
of AS [12]. Furthermore, in addition to its role as a decoy receptor for IL-33, excessive amounts
of sST2 may induce direct effects, modulating extracellular matrix remodeling and turnover
[26], progression of AS and consequent clinical deterioration.
The prognostic power of circulating sST2 has been demonstrated in patients with acute
myocardial infarction or in the context of acute dyspnea with or without heart failure
[13,15,17,18, 25]. Elevated sST2 levels were predictive of clinical deterioration and short and
mid-term prognosis in an additive manner to BNP. In the present study, sST2 levels were also
associated with increased cardiovascular risk. In the group of asymptomatic AS patients, sST2
and peak aortic jet velocity predicted symptom-free survival, whereas other clinical or echocar-
diographic variables or biomarkers (BNP or BNP ratio) did not. Asymptomatic AS patients
with a plasma sST2 level>23 ng/mL were more likely to develop symptoms and require aortic
valve surgery during follow-up. Interestingly, all these patients were truly asymptomatic since
they had a normal exercise test at study entry. These results demonstrate that sST2 could be
used to enhance the predictive value of BNP in patients with AS [27,28]. This is probably
related to the fact that the IL-33/ST2 pathway and sST2 directly participate in the regulation of
extracellular matrix remodelling and inflammation, two major events involved in the patho-
physiology of AS.
We acknowledge that our study has some limitations. Despite the examination of a reason-
able number of patients with AS, the subgroup of symptomatic AS patients remained relatively
small. sST2 measurements were not repeated during the follow-up period, and therefore the
prognostic value of serial sST2 changes could not be assessed. The relationship between ST2
and global and regional myocardial function was not assessable. In order to confirm the associ-
ation of sST2 with AS, further studies that would analyse serial changes of sST2 during patient
follow-up are required.
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